The atopic dermatitis (AD) market is on track to reach $16.7 billion across mature markets by 2030, according to data and analytics company GlobalData. 19 September 2024
Danish clinical-stage techbio firm Evaxion Biotech, which is developing AI-Immunology powered vaccines, announced new clinical Phase II data for its lead compound EVX-01. 9 September 2024
Danish dermatology specialist LEO Pharma has presented a range of new population-level and physician-reported data on the prevalence, severity and treatment of moderate to severe chronic hand eczema (CHE). 5 September 2024
Biocon Biologics has signed a settlement and license agreement with Johnson & Johnson that clears the way to commercialize its Bmab 1200, a proposed biosimilar to Stelara (ustekinumab), in Europe, the UK, Canada, and Japan. 3 September 2024
South Korea’s Celltrion yesterday announced the European Commission (EC) approval for the use of SteQeyma (CT-P43), an ustekinumab biosimilar referencing Stelara, for the treatment of multiple chronic inflammatory diseases. 27 August 2024
Danish dermatology specialist LEO Pharma’s Timber Pharmaceuticals subsidiary has announced disappointing results for the randomized, double-blind 12-week period of the ASCEND trial. 23 August 2024
San Diego, USA-based biotech AnaptysBio (Nasdaq: ANAB) yesterday announced the pricing of an underwritten offering of 2,750,498 shares of its common stock at a price of $36.50 per share, representing a premium of approximately 10% to Anaptys’ closing price on August 13, 2024. 15 August 2024
Shares of American dermatology company Verrica Pharmaceuticals had a roller-coaster start to the day after announcing what it called positive trial results. 14 August 2024
The US Food and Drug Administration (FDA) has approved Galderma’s Nemluvio (nemolizumab) as a pre-filled pen for subcutaneous injection for the treatment of adults with prurigo nodularis. 14 August 2024
The US subsidiary of South Korea’s Celltrion announced its US Food and Drug Administration (FDA)-approved biosimilar adalimumab-aaty has been added to the Costco member prescription program. 14 August 2024
Crown Laboratories, a privately held skincare company, and Nashville, USA-based Revance Therapeutics have entered into an agreement whereby the companies seek to merge the two complementary organizations. 13 August 2024
BioNTech released positive top-line data from the ongoing Phase II clinical trial in patients with unresectable stage III or IV melanoma whose disease had progressed following anti-PD-(L)1-containing treatment. 30 July 2024
California’s Arcutis Biotherapeutics, a biopharma developing innovations in immuno-dermatology, has announced the US commercial launch of Zoryve (roflumilast) cream 0.15% for the treatment of mild to moderate atopic dermatitis in adults and children down to age six years. 30 July 2024
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended seven novel medicines for approval at its July 2024 meeting. 26 July 2024
“Circle of Goodness,” one of Russia’s largest public funds, specializing on procurements of drugs for children with rare diseases, will begin procurements of the US drug Vyjuvek (beremagen heperpavec), which is designed for patients with epidermolysis bullosa (butterfly syndrome), reports The Pharma Letter’s local correspondent. 25 July 2024
Novartis, Boehringer Ingelheim and Celgene have presented positive data on their dermatology products at the American Academy of Dermatology meeting in San Francisco this weekend. 23 March 2015
The medicines cost watchdog the National Institute of Health and Care Excellence (NICE) has recommended Swiss pharma giant Novartis’ Xolair (omalizumab) as an option for add-on therapy for treating severe chronic spontaneous urticaria (CSU). 11 March 2015
US biotech firm KYTHERA Biopharmaceuticals said yesterday that the US Food and Drug Administration's Dermatologic and Ophthalmic Drugs Advisory Committee has voted unanimously to support the approval of ATX-101 (deoxycholic acid) injection. 10 March 2015
The European Commission has granted Ireland-headquartered Actavis' subsidiary Durata Therapeutics International marketing authorization for Xydalba (dalbavancin) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. 2 March 2015
A Phase IIb study of dupilumab, from Sanofi and Regeneron, has shown that the drug improved patient-reported outcomes in moderate-to-severe atopic dermatitis. 23 February 2015
Ireland-headquartered generics major Actavis has entered an agreement with Mayne Pharma to divest the US rights to the Doryx (doxycycline) brand acne treatment and related assets. 10 February 2015
Adding to recent marketing clearances in Japan and the European Union, the US Food and Drug Administration yesterday approved Swiss pharma giant Novartis’ Cosentyx (secukinumab) for the treatment of moderate-to-severe plaque psoriasis. 22 January 2015
The European Commission (EC) has approved Swiss pharma giant Novartis’ Cosentyx (secukinumab, formerly known as AIN457) as a first-line systemic treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy. 19 January 2015
US biotech firm Celgene’s European subsidiary has received marketing authorization from the European Commission (EC) for Otezla (apremilast), the company’s oral selective inhibitor of phosphodiesterase 4 (PDE4), in two therapeutic indications. 18 January 2015
Privately-held Spanish pharmaceutical company Ferrer says it has licensed commercialization rights for ozenoxacin 1% cream in Canada to local drugmaker Cipher Pharmaceuticals. 7 January 2015
Independent Danish dermatology specialist Leo Pharma has submitted a New Drug Application to the US Food and Drug Administration for calcipotriene/betamethasone dipropionate aerosol foam 0,005%/0,064% for the treatment of psoriasis vulgaris. 6 January 2015
Japanese drugmaker Chugai Pharmaceutical says that, on December 24, the Tokyo District Court granted Chugai an overall victory for the first instance demanding the suspension of patent infringement of the manufacturing process patent owned by Chugai (Patent No 3310301), related to Oxarol (maxacalcitol) ointment. 29 December 2014
The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved Swiss pharma giant Novartis’ Cosentyx (secukinumab) for the treatment of both psoriasis vulgaris and psoriatic arthritis. 26 December 2014
The Food and Drug Administration has approved Israeli generics giant Teva Pharmaceutical Industries’ Granix (tbo-filgrastim) Injection for self-administration by patients and caregivers. 24 December 2014
RNA technology specialist RXi Pharmaceuticals Corp has entered into a global licensing agreement with Hapten Pharmaceuticals for Samcyprone. 19 December 2014
The first biologic to treat atopic dermatitis, French pharma major Sanofi (Euronext: SAN) and US biotech firm Regeneron Pharmaceuticals’(Nasdaq: REGN) dupilumab, could launch in the USA by second-quarter 2017. 4 December 2014
USA-based Amgen, the world’s leading independent biotech firm, and Anglo-Swedish drug major AstraZeneca have concluded their AMAGINE-2 Phase III trial of two doses of brodalumab, finding that it met its primary endpoints in moderate-to-severe plaque psoriasis. 26 November 2014
US biotech Regeneron Pharmaceuticals and French pharma major Sanofi have said that the US Food and Drug Administration has granted Breakthrough Therapy designation to dupilumab for the treatment of adults with moderate-to-severe atopic dermatitis (AD). 25 November 2014
A total of 10 new medicines have been recommended for approval at the November 2014 meeting of the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). 22 November 2014